816PDCLINICAL ACTIVITY OF SUNITINIB RECHALLENGE IN METASTATIC RENAL CELL CARCINOMA (MRCC) – RESULTS OF THE RESUME STUDY

Abstract Aim: Sunitinib is a front-line standard of care in mRCC patients. Several studies have shown that a 2nd line with a TKI after sunitinib progression is an effective treatment in mRCC. We assessed the efficacy and tolerability of a sunitinib rechallenge in 3rd line or more after progression w...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Annals of oncology 2014-09, Vol.25 (suppl_4), p.iv283-iv284
Hauptverfasser:	Oudard, S., Goupil, M. Gross, Geoffrois, L., Guillot, A., Chevreau, C., Deville, J.L., Falkowski, S., Boyle, H., Palmaro, M. Baciuchka, Gimel, P., Laguerre, B., Laramas, M., Pfister, C., Topard, D., Rolland, F., Legouffe, E., Amela, E., Abadie-Lacourtoisie, S., Mahi, N.
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!